BCHT(SH:688276) Ge Long Hui A P P·2026-02-26 08:24Core Viewpoint - The financial performance of Baike Biotech (688276.SH) for the fiscal year 2025 shows a significant decline in revenue and net profit, primarily influenced by various factors affecting public awareness and willingness to consume vaccines [1] Financial Performance - Total operating revenue for 2025 was 592 million yuan, a year-on-year decrease of 51.85% [1] - Net profit attributable to the parent company was -272 million yuan, representing a year-on-year decline of 217.22% [1] - Net profit attributable to the parent company, excluding non-recurring gains and losses, was -289 million yuan, down 225.71% year-on-year [1] Factors Influencing Performance - The decline in revenue was mainly due to factors such as public awareness of diseases and willingness to consume vaccines [1] - Some confirmed revenue from the herpes zoster live attenuated vaccine could not be realized due to expiration and subsequent returns, contributing to the revenue drop [1] - To enhance public awareness of herpes zoster prevention and fulfill corporate social responsibility, the company actively promoted welfare projects and adjusted prices, leading to a decrease in the unit price of the herpes zoster vaccine and further revenue decline [1] - Additionally, a decrease in newborn birth rates and intensified market competition resulted in reduced sales of the varicella live attenuated vaccine, further impacting revenue [1]